Newsletter | June 14, 2025

06.14.25 -- Life Science Leader Best Of May

MAY'S BEST FEATURED EDITORIAL

Adapting To Change In The Era Of Tariffs, Tax And Regulatory Changes

By Christine Kachinsky

Life sciences companies face an impending “tax policy trifecta” including potential TCJA expiration, U.S. trade and regulatory overhaul, and implementation of the OECD’s global minimum tax regime.

MAY'S BEST INDUSTRY INSIGHTS

Assessing E&Ls From Single-Use Systems Used In ATMP Production

Explore the impact of extractables and leachables (E&Ls) in cell and gene therapy development. Learn how to qualify single-use systems and use cell-painting assays to assess E&L effects.

Why Community-Rooted Recruitment Is The Future Of Clinical Trials

Despite clinical trial awareness campaigns and site expansions, trials continue to fall short in reaching the patients who need them most, resulting in a shift toward community-rooted recruitment.

A Dip In NAS Launches Annual Review 2025 Supplement

Even though new active substance launches declined 11% in 2024, this still represented the fourth-highest total of newcomers to the pharma runway recorded and predictions remain good for 2025.